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Resource allocation to brain research in Switzerland
Abstract
QUESTIONS UNDER STUDY: This study represents a first attempt at estimating Swiss resource
allocation to brain research including both public and private spending. METHODS: In order to estimate
public spending (by governments and charities) a survey was conducted to evaluate the way brain
research is funded across Europe and especially in Switzerland. Industry funding was measured using
different approaches including a survey of pharmaceutical expenditures and the costs of developing new
drugs. RESULTS: Private spending is at a reasonable level because a highly developed Swiss
pharmaceutical industry invests significantly in this branch of science. However, public spending is at a
low level compared to other European countries, although Switzerland is the only European country
where the total funding per capita exceeds that of US funding. CONCLUSIONS: A detailed
investigation of Swiss resource allocation to different branches of biomedical research is warranted.
Brain research should be an important part of such a study. The United States and the European Union
have selected brain research as one of their priority areas within health related research. The present
figures indicate that this may also be justified in Switzerland.
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Questions under study: This study represents a
first attempt at estimating Swiss resource alloca-
tion to brain research including both public and
private spending. 
Methods: In order to estimate public spending
(by governments and charities) a survey was con-
ducted to evaluate the way brain research is
funded across Europe and especially in Switzer-
land. Industry funding was measured using differ-
ent approaches including a survey of pharmaceu-
tical expenditures and the costs of developing new
drugs.
Results: Private spending is at a reasonable
level because a highly developed Swiss pharma-
ceutical industry invests significantly in this
branch of science. However, public spending is at
a low level compared to other European coun-
tries, although Switzerland is the only European
country where the total funding per capita ex-
ceeds that of US funding. 
Conclusions: A detailed investigation of Swiss
resource allocation to different branches of bio-
medical research is warranted. Brain research
should be an important part of such a study. The
United States and the European Union have se-
lected brain research as one of their priority areas
within health related research. The present fig-
ures indicate that this may also be justified in
Switzerland. 
Key words: funding; brain research; brain disor-
ders; cost-benefit; Switzerland
Summary
Brain research (neuroscience) provides a bet-
ter understanding of normal human brain func-
tion. This has implications for every aspect of
modern life and may improve human adaptation
to modern society. Brain research is also crucial in
order to better prevent, diagnose and treat brain
diseases (neurological and psychiatric disorders).
Brain diseases are prevalent and cause approxi-
mately one third of the total burden of all diseases
[1]. The economic cost of brain diseases in Eu-
rope is more than € 386 billion [2] and probably
equals the expense of cancer and heart diseases
combined. The cost of brain diseases in Switzer-
land is about € 9 billion [3].
Given the importance of brain research, the
question arises as to whether this branch of re-
search receives sufficient funding. To date, data on
resource allocation to brain research have been
almost totally lacking. Recently, the European
Brain Council together with the research organi-
zation, European Health Economics (EHE), con-
ducted a large European-wide survey describing
the Resource Allocation to Brain Research in
 Europe (RABRE) [4]. The present report details
data for Switzerland on the resource allocation to
brain research. Public funding, defined as charity
and government funding, and private funding,
 essentially meaning industry funding, were both
included. We compare these data to those of other
countries in Europe.
Introduction
No financial
 support declared.
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The total funding of brain research in Europe
is shown in fig. 1. 
The total funding of brain research in Europe
was estimated at € 4.1 billion in 2005. Charities
and Government contributed € 855 million. In-
dustry funding was estimated at € 3.25 billion.
With regard to Swiss funding, the public funding
bodies asked and the funding bodies that have re-
sponded are listed in table 1. 
The total public funding in Switzerland
amounts to € 8.6 million. These figures are in-
cluded in the European calculations, which show
public spending for brain research in the different
European countries (fig. 2). 
It can be seen that Switzerland, among the
wealthy European countries, is in the middle
336Resource allocation to brain research in Switzerland
The RABRE study examined all known sources of
funding, including governmental grants as well as charita-
ble and industry funding. To estimate public spending
(both by governments and charities), a survey was con-
ducted that evaluated the way brain research is funded
across Europe. Charitable organisations (organisations
for public benefit that rely on donations for financial sup-
port) and private not-for-profit organisations (whose se-
curities are not offered to the public) were combined into
the term “charities” to avoid any confusion. By directly
contacting the primary sources of research funding, the
estimate represented the money spent by European insti-
tutions rather than the actual total research investments
at European research institutions. The latter may include
research funded from outside Europe, for example, the
National Institutes of Health (NIH) in the US. The re-
sponse rate of public agencies and an industry-funding es-
timate in Switzerland were sufficient. Imputations were
made for countries with insufficient response rates to ac-
count for omitted data. Country and disorder specific
spending is hence extrapolated from the data received and
should be treated with some caution. The national esti-
mates were corrected for price level and inflated to 2005
values. 
Industry funding was measured by three different
approaches: (1) by using a worldwide survey of pharma-
ceutical expenditure according to disease area issued by
the Centre for Medicines Research (CMR) [5]; (2) by
considering the published cost of developing a new drug
and applying that cost to the number of new chemical en-
tities [NCE(s)] launched in Europe in the past decades
[6]; and (3) by applying the share of drugs for brain dis-
eases that have entered the market between 1985 and
2004 to total R&D (research and development) expendi-
ture by pharmaceutical companies in Europe over the
same period of time [7]. Disorder specific expenditures
were estimated based on the share of brain disorder spe-
cific drugs that have entered the market. Country specific
estimates were based on national pharmaceutical industry
contribution to total R&D in Europe according to Euro-
pean Federation of Pharmaceutical Industries and Associ-
ations (EFPIA) [7]. 
Methods 
Results
0
100
200
300
400
500
600
700
Af
fe
ct
ive
di
so
rd
er
s
Pa
rk
in
so
n
Ep
ile
ps
y
St
ro
ke
Sc
hi
zo
ph
re
ni
a
M
ig
ra
in
e
De
m
en
tia
M
ul
tip
le
Sc
le
ro
sis
A
dd
ic
tio
n
An
xie
ty
di
so
rd
er
s
Br
ai
n 
tu
m
ou
r
Tr
au
m
at
ic
Br
ai
n 
In
ju
ry
O
th
er
 b
ra
in
di
so
rd
er
s
Ba
sic
 re
se
ar
ch
 
m
ill
io
n
Industry funding Public funding
 
Figure 1
Total funding of brain
research by disorder
in Europe (2005).
Organization Funding type Reported 
Spending
Association Alzheimer Suisse Charity yes
Centre for Technology Government Agency yes
and Innovation
Schweizerische Multiple Charity yes
Sklerose Gesellschaft
Schweizerische Charity yes
Parkinsonvereinigung
Swiss Heart Foundation Charity yes
Swiss National Science Government Agency yes
Foundation
Table 1 
Public funding agencies included in the study 
and their reported donation (2005).
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range of public resource allocation to brain re-
search and also in the middle range when popula-
tion size is taken into account. Private funding in
Switzerland was estimated to be more than € 383
million in the European study. The lowest esti-
mate of funding in Switzerland is thus more than
€ 390 million per year with the possibility of an
added 10% from biotech companies. Fig. 3 shows
how Swiss brain research funding is distributed
according to different disease groups and basic re-
search. 
It was not possible to obtain specific figures
from universities on their spending on brain re-
search and university spending is hence not
 included. European estimates [4, 8] indicate, how-
ever, that spending on brain research in institu-
tions of higher learning in Switzerland is around
€ 12 million, virtually all of it for basic research.
The distribution of public funding for disease
 related research versus basic research is likely to
be roughly equal. Within the different disease
areas, the best funded diseases in Switzerland are
affective disorders and the least funded is Trau-
matic Brain Injury (TBI). If this is related to the
burden of the individual diseases (fig. 4), the rela-
tively best funded disease is however Parkinson’s
disease at 24% of the costs and the relatively least
funded disease is TBI (0.3%) and most of the
mental disorders. 
The Swiss funding of brain research is € 53
million per million inhabitants. The funding in
the United States is € 49 million per million in-
habitants [9], in Europe it is € 8.3 and in Denmark
€ 22 [12] (Fig.5). Switzerland is the only Euro-
pean country with a higher per capita research
spending than the US, due to the large estimate of
private funding in Switzerland. Regarding public
funding for brain research, Ireland had the high-
est level per capita (€ 6.7), followed by the UK 
(€ 5.2) and Hungary (€ 2.7). The lowest levels
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Figure 2
Public spending on
brain research per
country (2005).
* Reference countries
for imputations
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Figure 3
Public and industry
research funding per
disorder in Switzer-
land (2005).
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Resource allocation to different branches of
research has so far not been based on careful
weighting of the size of the problem and the pos-
sibilities for achievement. It has mostly been
driven by the activity level within a particular
branch of science in a particular country com-
bined with certain political preferences. The Lis-
bon agreement of the EU related the necessary
research spending to the gross national product
and requested that by 2010 general research fund-
ing should be 3% of the gross national product
with 2% private funding and 1% public funding
[10]. Relating research expenditure to gross na-
tional product could also be expressed as a rela-
tion to gross national spending, which roughly
has to equal the national product. A next step in
this line of thinking is to compare research spend-
ing to the cost of the field of study. Brain research
expenditure should thus be compared to the cost
of brain diseases. However, the importance of un-
derstanding normal human brain function should
also be taken into account. In contrast, research
into other organs such as the heart or the kidney
is mostly or exclusively important because of pre-
vention and treatment of diseases related to those
organs. 
If one accepts the argument that research
 effort in a particular field should be related to its
cost, then it becomes important to know the
 resources spent on different fields of research.
However, very little work has been done in
Switzerland or in other countries to elucidate this
issue. The present study is to our best knowledge
the first estimation of resource allocation to brain
research in Switzerland and it is based on the first
ever study of Research Allocation to Brain Re-
search in Europe. Since the data brought here are
derived from the European study, it is possible to
compare Swiss figures to the figures of other Eu-
ropean countries and also to the United States.
Likewise, we can compare the Swiss spending to
the data that are now available on the cost of dis-
eases of the brain in Switzerland [3] and to the
European figures for the burden of brain diseases
based on WHO data [1]. Brain tumour and trau-
matic brain injury are relatively rare in compari-
son to other brain disorders, but very costly per
case. Migraine and mental disorders are very
prevalent and cause a heavy monetary burden to
society. In this respect the present data show that
especially research into mental disorders is dra-
matically under funded in Switzerland. A similar
pattern emerges in Europe, as mental disorders
taken together make up 69% of the total cost of
brain disorders, whereas the brain research fund-
ing makes up about 35% [4].
Accuracy of the present data
Since this is a pioneering study it also has sig-
nificant weaknesses. Not all funding bodies have
been identified in our search and not all funding
bodies responded. It is unlikely that major fund-
ing bodies were not identified, but a relatively
large number of small foundations etc. may have
remained undetected in the European survey.
Other funding bodies have not been able to allo-
cate their donations to different topics and hence
were unable to give a figure for their donations to
338Resource allocation to brain research in Switzerland
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Brain research funding per capita for Switzerland, Europe, Denmark and US (2005).
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Figure 4
Brain research funding as percentage of costs in Switzerland (2005).
Discussion
were found in Latvia (€ 0.14) and Malta (€ 0.15).
Switzerland (€ 1.1) had a per capita spending
shortly below the European average, estimated at
€ 1.2 [4]. The US per capita public spending is 
€ 20.8.
335-339 Jaeger 12081.qxp  3.6.2008  15:16 Uhr  Seite 338
339
1 Olesen J, Leonardi M. The burden of brain diseases in Europe.
Eur J Neurol. 2003;10:471–7.
2 Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of
disorders of the brain in Europe. Eur J Neurol. 2005;12
(Suppl1):1–27.
3 Jäger M, Sobocki P, Rossler W. Cost of disorders of the brain in
Switzerland. With a focus on mental disorders. Swiss Med
Wkly. 2008;138:4–11.
4 Sobocki P, Lekander I, Berwick S, Olesen J, Jönsson B. Re-
source Allocation to Brain Research in Europe. Eur J Neurosci.
2006;24(10):2691–3.
5 CMR: The 2005/2006 CMR International R&D Factbook In-
Surrey, Centre for Medicines Research International (CMR),
2006.
6 DiMasi JA, Hansen RW, Grabowski HG. The price of innova-
tion: new estimates of drug development costs. J Health Econ.
2003;22:151–85.
7 EFPIA: The Pharmaceutical Industry in Figures. In, European
Federation of Pharmaceutical Industries and Associations
(EFPIA), 2006.
8 Braintrack: Braintrack University Index – Europe. In, Brain-
track, 2006.
9 NIH: Estimates of Funding for Various Diseases, Conditions,
Research Areas (last updated sept 21, 2005). In, National Insti-
tutes of Health (NIH) 2005.
10 Eurostat: First preliminary results: Research & Development
in the EU. In, Eurostat, 2005.
S W I S S  M E D  W K LY 2 0 0 8 ; 13 8 ( 2 3 – 2 4 ) : 3 3 5 – 3 3 9  ·  w w w. s m w. ch
11 Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS.
Effect of a US National Institutes of Health programme of
clinical trials on public health and costs. Lancet. 2006;367:
1319–27.
12 Olesen J, Lekander I, Sobocki P. Resource allocation to brain
research in Denmark: an example for other European coun-
tries. Eur J Neurol. 2007;14:667–71.
13 Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of bur-
den of schizophrenia and psychotic disorders. Eur Neuropsy-
chopharm. 2005;15:399–409.
Correspondence: 
M. Jäger
Psychiatric University Hospital
Department of General and Social Psychiatry
Lenggstrasse 31
CH-8032 Zürich
Switzerland
E-Mail: Matthias.jaeger@puk.zh.ch
brain research. A specific Swiss study based on
similar methodology as the European study is
warranted. Such a study would identify private
and public spending more efficiently but would
not be comparable to data from other countries. It
would still be relatively uncertain because many
funding bodies do not know to what extent they
fund brain research as opposed to other kinds of
research. In order to acquire really precise data,
funding bodies will need to start recording which
types of research they are funding in a systematic
and uniform way. The biggest uncertainty in the
present study, is that university funded brain re-
search was not included. This was estimated from
figures originating at Uppsala University in Swe-
den, and it is by no means certain that the esti-
mate for Swiss university spending is precise.
Some of the uncertainties tend to overesti-
mate, other to underestimate funding so that the
total figure for research allocation to brain re-
search is likely to be in the correct range. In the
European study, sensitivity analysis was conducted
and indicated that the results were probably cor-
rect within ±25%. In the estimate of industry
funding it is assumed that the share of CNS drugs
marketed reflects the investments today, but since
CNS drugs in pipeline are increasing, the correct
figure is probably higher. In addition, the Swiss
estimate is based on Switzerland’s share of total
R&D and it is assumed that this share also ac-
counts for CNS but this might not be the case.
The spending by these pharmaceutical companies
is most likely spread over several countries, mak-
ing it difficult to account for how much is Swiss
private funding. Even though the total estimate
from the European study of industry funding in
Europe is fairly accurate (±10%), there is great
uncertainty when reduced to a national level.  
Comparisons 
The total estimate of resource allocation to
brain research in Switzerland is € 392 million and
the cost of brain disease in Switzerland has been
estimated at € 9 billion [3]. Thus, research invest-
ment equals 4.4% of the costs. Of this 98% is pri-
vate (industry) and 2% is public, divided into gov-
ernmental 92% and charities 8%. In these calcula-
tions, the enormous importance of understand-
ing normal brain function is not included. Whilst
industry funding of brain research thus reaches
the Lisbon goals of the EU, public funding and
particularly government funding is very much
lower than the Lisbon goals. Compared to the
United States, Swiss public funding of brain re-
search is low, as it is for most other branches of
research, as the United States overall spends more
of its gross national product on research than do
the European countries [11]. As in many other
countries, in Switzerland resource allocation fol-
lows outdated legal regulations and is not based
on research needs, i.e. based on the prevalence,
 respectively the burden, of disorders. The course
of brain disorders is often chronic and character-
ized by a high degree of disability thereby gener-
ating high indirect costs [13]. A new legal general
framework that considers the burden of diseases is
required. 
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